What is the latest price of domestically produced Avonib in 2024?

Ivosidenib (Ivosidenib) The original drug has been approved by the National Medical Products Administration in 2022 for domestic marketing, and is sold under the name Tusovo Ivosidenib tablets, but it is not covered by medical insurance. It is understood that there is no relevant pharmaceutical factory in China that produces ivosidenib, and it may be in the clinical trial stage. At some point in the future, a domestically produced medicine of ivosidenib may be available.

Avosidenib is an isocitrate dehydrogenase1 (IDH1) inhibitor approved for use in the United States and Europe. It is indicated for the treatment of patients susceptible to IDH1 mutations: Newly diagnosed acute myeloid leukemia (AML), in combination with azacitidine or as monotherapy in adults with newly diagnosedAML who have comorbidities that preclude the use of intensive induction chemotherapy, or relapsed or refractory acute myeloid leukemia, or adults with previously treated locally advanced or metastatic cholangiocarcinoma, or adults with relapsed or refractory myelodysplastic syndrome.

The domestically sold Ivoniboriginal drug specifications0.25g*60 tablets are priced as high as RMB 100,000 per box, while the U.S. original version sold overseas is priced as high as more than 200,000 RMB per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap. Please consult Yaode Medical Consultant for specific prices and drug details.